HealthTech: GE HealthCare Partners with Biofourmis to Advance Home Hospitalization and Reduce Medical Costs

Biofourmis, a company participating in the Vintage Altaroc Odyssey , has developed a cutting-edge connected technology platform for patient monitoring. For its part, the global giant GE HealthCare is dedicated to the development, manufacturing, and marketing of complementary products, services, and digital solutions. Their joint innovations are used in the diagnosis, treatment, and monitoring of patients around the world.

This strategic partnership provides a direct response to the critical rise in healthcare costs, exacerbated by shortages of medical staff and capacity constraints (lack of beds) in hospitals. Large-scale distribution of Biofourmis’ solutions through GE HealthCare’s sales network began in the United States in the first quarter of 2024.

Massive savings for hospitals and healthcare systems

The collaboration focuses on two major objectives: reducing unplanned hospital readmissions and shortening the length of hospital stays. Home care programs, which include remote monitoring and virtual appointments, have proven particularly effective in promoting patient recovery and safety. By staying at home, patients avoid the risks of falls and nosocomial infections (illnesses contracted in the hospital).

The financial impact of this digital transition is immediately apparent for healthcare facilities:

• A 15% to 25% reduction in readmissions: Thanks to ongoing follow-up after hospital discharge, serious relapses are anticipated and prevented.
• Cost savings per patient: Reducing the length of a hospital stay by 2 to 3 days saves an average of $3,000 to $5,000 per episode of care, freeing up beds for emergency cases.
• Patient satisfaction: Remote care solutions have recommendation rates exceeding 90%, as patients much prefer to recover in the comfort of their own homes.

Technology on Your Wrist: Clinical Sensors and Artificial Intelligence

GE HealthCare is integrating Biofourmis's home care solutions into its own patient monitoring portfolio. This system relies on high-precision medical equipment and intelligent analysis software:

1. Lightweight and accurate portable devices

Unlike mainstream smartwatches, Biofourmis uses clinical-grade sensors (in the form of patches applied to the chest or wristbands) that have been approved by health authorities. They continuously measure the following in real time:

• The heart's electrical activity (electrocardiogram or ECG),
• Heart rate and respiratory rate,
• Body temperature and blood oxygen levels,
• Level of physical activity and posture (fall detection).

2. FDA-validated predictive algorithms

The platform’s strength lies in its intelligent algorithms (called Biovitals), which have been approved by the U.S. FDA. Instead of issuing an alert only when the patient is already unwell, the artificial intelligence analyzes subtle, invisible changes in vital signs. It can predict a deterioration in health (for example, a relapse related to heart failure) up to 14 days before the first visible symptoms appear, allowing doctors to adjust treatment remotely.

Comparison: Biofourmis vs. Traditional Solutions

The medical telemonitoring market has become highly structured. Biofourmis’s agile approach is shaking up the industry’s established players:

Voices from the Field: The Impact on Patients and Caregivers

The adoption of these technologies is positively transforming users' daily lives and redefining the way healthcare professionals work:

“I was very worried about going home after my heart surgery. With the Biofourmis sensor on my wrist, I knew the hospital was keeping an eye on me remotely. My doctor was able to adjust my medications twice in a month without me having to travel or wait in line at the emergency room again.” — Jean-Pierre, 68, a patient using the device at home.

A Breath of Fresh Air Amid the Medical Staff Shortage

For nurses and doctors, this technology is fundamentally changing how they manage their time. Instead of suffering from “alarm fatigue” (dozens of alarms going off at the same time in the hospital for minor reasons), medical staff use a centralized dashboard. Artificial intelligence sorts patients by priority. Caregivers contact only those patients whose data indicate a genuine cause for concern, thereby optimizing their work time by nearly 40%.

International expansion and encouraging financial outlook

Following a successful launch in the U.S. market in 2024, GE HealthCare and Biofourmis are implementing a phased international expansion strategy:

• Late 2025 – Some time in 2026: Launch of home hospitalization programs in the United Kingdom and Germany, two countries facing significant challenges with hospital overcrowding.
• Horizon : Expansion of the network into the Asia-Pacific region (particularly Japan and Australia), where the aging population requires urgent remote care solutions.

For investors, GE HealthCare’s financial strength provides a particularly solid foundation. With a market capitalization of $40.56 billion, the company is on a positive growth trajectory, with revenue up 6.6% by the end of 2023. Its gross profit margin of 40.52% demonstrates excellent financial stability and strong operational efficiency.

As Ross Armstrong, CEO of Biofourmis Care, puts it, this partnership combines the power of data and technology to build a modern healthcare system that is entirely focused on patient well-being, from the hospital all the way to the patient’s living room.